for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bausch Health Companies Inc

BHC.TO

Latest Trade

38.33CAD

Change

0.00(0.00%)

Volume

471,529

Today's Range

38.20

 - 

38.96

52 Week Range

24.89

 - 

42.15

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
38.33
Open
38.70
Volume
471,529
3M AVG Volume
12.15
Today's High
38.96
Today's Low
38.20
52 Week High
42.15
52 Week Low
24.89
Shares Out (MIL)
352.43
Market Cap (MIL)
13,747.99
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Bausch Health Companies Inc Earnings Call

Latest Developments

More

Bausch + Lomb - Announced U.S. Launch Of Expanded Parameters For Biotrue Oneday For Astigmatism Daily Disposable Contact Lenses

Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction

Bausch Health Announces Resolution Of BRYHALI Lotion Intellectual Property Litigation With Glenmark

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bausch Health Companies Inc

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Contact Info

2150 Saint-Elzear Blvd W

+1.514.7446792

https://www.bauschhealth.com

Executive Leadership

Joseph C. Papa

Chairman of the Board, Chief Executive Officer

Paul S. Herendeen

Chief Financial Officer, Executive Vice President

Thomas J. Appio

President & Co-Head Bausch + Lomb/International

Joseph F. Gordon

President & Co-Head Bausch + Lomb/International

William Douglas Humphries

President of Ortho-Dermatologics

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

9.7K

2017

8.7K

2018

8.4K

2019(E)

8.6K
EPS (USD)

2016

5.470

2017

3.830

2018

3.970

2019(E)

4.373
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.23
Price To Book (MRQ)
4.22
Price To Cash Flow (TTM)
6.88
Total Debt To Equity (MRQ)
949.48
LT Debt To Equity (MRQ)
945.45
Return on Investment (TTM)
-2.12
Return on Equity (TTM)
-1.86

Latest News

Latest News

Bausch Health agrees to pay $1.21 billion to settle share price lawsuit

Bausch Health Cos Inc <BHC.TO> said on Monday it settled a class action lawsuit for $1.21 billion related to a drop in the drugmaker's shares during 2013-2015.

UPDATE 1-Bausch Health agrees to pay $1.21 bln to settle share price lawsuit

Bausch Health Cos Inc said on Monday it settled a class action lawsuit for $1.21 billion related to a drop in the drugmaker's shares during 2013-2015.

Pharmacy chains sue Bausch Health, other drugmakers for overcharging for diabetes drug

Three pharmacy chains, including Walgreens Boots Alliance <WBA.O>, have filed a lawsuit against drugmakers Bausch Health Inc <BHC.TO>, Assertio Therapeutics <ASRT.O> and Lupin Ltd <LUPN.NS>, seeking damages for overcharging for Bausch's diabetes drug Glumetza.

Convictions of ex-Valeant and Philidor executives are upheld, payouts reduced

A U.S. appeals court on Thursday upheld the convictions of two drug industry executives for defrauding Valeant Pharmaceuticals International Inc through a multimillion-dollar kickback scheme, but reduced how much they must forfeit for their crimes.

BRIEF-Bausch Health Files Lawsuit Against Sandoz Inc

* BAUSCH HEALTH FILES LAWSUIT AGAINST SANDOZ FOR INFRINGEMENT OF PATENTS PROTECTING XIFAXAN® 550 MG TABLETS

Bausch Health's lotion for plaque psoriasis wins FDA approval

The U.S. Food and Drug Administration on Thursday approved Bausch Health Companies Inc's topical plaque psoriasis treatment, which is expected to be a key revenue driver for the company.

Bausch Health's lotion for plaque psoriasis wins FDA approval

Bausch Health Companies Inc said on Thursday the U.S. Food and Drug Administration has approved its lotion for plaque psoriasis in adults.

Ex-Valeant, Philidor executives get prison for fraud

A former executive at Valeant Pharmaceuticals International Inc and the former head of a start-up mail-order pharmacy were sentenced to one year in prison on Tuesday after being convicted of defrauding the drugmaker through a secret kickback scheme.

Ex-Valeant, Philidor executives get prison for fraud

A former executive at Valeant Pharmaceuticals International Inc and the former head of a start-up mail-order pharmacy were sentenced to one year in prison on Tuesday after being convicted of defrauding the drugmaker through a secret kickback scheme.

Bausch Health's plaque psoriasis lotion gets tentative FDA approval

Bausch Health Cos Inc, formerly Valeant Pharmaceuticals, said on Monday it received tentative U.S. approval to market its plaque psoriasis lotion, Bryhali.

Bausch Health's plaque psoriasis lotion gets tentative FDA approval

Bausch Health Cos said on Monday it received tentative approval from the U.S. health regulator to market its plaque psoriasis lotion, Bryhali.

Bausch Health unit moves to settle charges it misled investors -SEC

Salix Pharmaceuticals, a unit of Bausch Health Companies Inc <BHC.TO>, has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company's prospects, the SEC said on Friday.

Bausch Health subsidiary moves to settle charges it misled investors -SEC

Salix Pharmaceuticals, a unit of Bausch Health Companies Inc, has moved to settle charges brought by the U.S. Securities and Exchange Commission that it misled investors about the company's prospects, the SEC said on Friday.

UPDATE 2-Bausch Health beats profit estimates, promises to cut debt

* Toronto shares rise 6 pct; New York shares 7.5 pct (Adds details from conference call, analyst comment, updates share price)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up